LONDON, May 25, 2023 (GLOBE NEWSWIRE) — Small Pharma Inc. DMT DMTTF (The “Pursue” or “Small pharmaceutical industry“), a biotechnology company focused on short-term psychedelic-assisted therapies for mental illness, today announces an update to its intellectual property (“IP“) portfolio, showing the significant progress the company has already made in 2023.

Small Pharma aims to protect its pipeline programs through a multi-layered IP strategy with four core protection areas. These areas of protection include: composition of matterwhich covers novel drug substances; Medicinal useincluding therapeutic compositions and their medicinal uses; drug product, including pharmaceutical formulations; And Synthetic waycovering the novel and efficient large-scale synthesis of high-purity drug substances.

Since the IP portfolio was last updated on February 1, 2023, the Company has secured five new issued patents, with three more expected to be issued by May 31, 2023. In addition, the company has received five patent approval notices. The additional IP covers the four focus areas of protection and multiple markets, strengthening the company’s international IP position.

The new patent grants and notifications of approval are summarized below.